# Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) Lymphoma

> **NCT00656812** · PHASE2 · COMPLETED · sponsor: **Arbeitsgemeinschaft medikamentoese Tumortherapie** · enrollment: 40 (estimated)

## Conditions studied

- Lymphoma of Mucosa-Associated Lymphoid Tissue

## Interventions

- **DRUG:** Rituximab
- **DRUG:** 2-CdA

## Key facts

- **NCT ID:** NCT00656812
- **Lead sponsor:** Arbeitsgemeinschaft medikamentoese Tumortherapie
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2013-12-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00656812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00656812, "Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) Lymphoma". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00656812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*